Abstract
ABSTRACT Introduction Dry eye disease is a prevalent, multifactorial disease characterized by loss of tear film homeostasis. A myriad of ocular therapeutics is commercially available and in development for personalized management of dry eyes. Recently, Varenicline solution nasal spray (VNS) received approval from the US Food and Drug Administration for the treatment of dry eyes. Areas covered This review explores the current mainstay treatments for dry eyes and the role of VNS in addressing unmet needs in the treatment of dry eye disease. A PubMed and MEDLINE keyword search on Tyrvaya and Varenicline nasal solution spray was performed as a part of the inclusion criteria. Varenicline solution nasal spray has been shown to be well tolerated and demonstrated to provide clinically significant improvement in patients with dry eyes Expert opinion Treatment of dry eye disease with VNS may be most beneficial in patients with limited upper-body mobility, dexterity issues, tremors, and glaucoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
